Navigation Links
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
Date:11/18/2010

8, the Company's targeted cytotoxic drug in which doxorubicin, a well known chemotherapeutic agent, is linked to [D-Lys(6)]-luteinizing hormone releasing hormone (LHRH), in women with histologically confirmed LHRH-R positive advanced (FIGO III or IV) or recurrent endometrial cancer. Patients received a recommended dose of 267 mg/m2 by intravenous infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. Response rate per Response Evaluation Criteria in Solid Tumors (RECIST) was defined as primary endpoint. Secondary endpoints were safety, time-to-progression (TTP) and overall survival (OS). Results In all, 44 patients entered the study. Of these, 1 patient was withdrawn prior to start of treatment and 2 patients entered as replacement for patients withdrawn for reasons other than progressive disease. Of 43 patients treated with AEZS-108, 39 were evaluable for efficacy. Responses confirmed by independent review included 2 patients with complete response (CR; 5.1%), 10 patients with partial response (PR; 25.6%), and 17 patients with stable disease (SD; 43.6%). Based on those data, an Overall Response Rate (ORR = CR+PR) of 30.8 % and a Clinical Benefit Rate (CBR = CR+PR+SD) of 74.4% can be estimated. Responses were also achieved in patients with prior chemotherapy, 1 CR, 1 PR and 2 SDs in 8 of the patients pre-treated with platinum/taxane regimens. Median time to progression (TTP) and overall survival (OS) were 7 months (30 weeks) and 14.3 months (62 weeks), respectively.

Overall, tolerability of AEZS-108 was good and commonly allowed retreatment as scheduled. Only one patient (2%) had a dose reduction, and 17 (8%) courses were given with a delay, including also 11 cases in which delay was not related to toxicity. Severe (Grade 3 or 4) toxicity was mainly restricted to rapidly reversible hematologic toxicity (leukopenia/neutropenia) associated with fever in 1 case only, a patient who had been treated only 3 weeks after a surgery. G
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
2. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
4. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
5. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
6. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
7. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
8. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
9. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
10. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
11. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 5 BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC), ... products, announced today that,it has signed an agreement ... future royalty obligations for Peyronie,s disease by buying ... payment., BioSpecifics has modified its previously announced ...
... to Expand Business Development Efforts, SALT LAKE ... company,focused on the development of molecular diagnostic and ... today that Joe Ross has,joined the executive management ... Initiatives., In this new role, Ross will ...
... BFRM ) today announced its financial results for the ... sales were $16.7,million for the quarter ended June 30, 2008 ... 2007, an increase of $1.3 million or 8.4%.,The net loss ... as,compared to a net loss of $4.9 million for the ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Axial Biotech appoints new Vice President of Strategic Initiatives 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9
(Date:6/24/2015)... This report provides market analysis of the ... It contains an analysis of the drivers, challenges, and ... from the short, medium, and long term perspective landscapes. ... and technology trends that currently, prevail in the market. ... to efficiently manage the increasing marine traffic and increasing ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... 2015   MedNet Solutions , an innovative ... spectrum of clinical research, is pleased to announce ... the company,s intuitive, flexible and affordable cloud-based eClinical ... Stevie® Award by the American Business Awards ... category.  The American Business Awards are considered the ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... Elsevier, a world-leading provider of scientific, technical ... leading German scientist, Professor Dr. Manfred T. Reetz ... Meerwein Research Professor at Philipps-Universitt, Marburg, has been ... Creativity in Organic Chemistry. The Executive ...
... demonstrated how a species of flatworm overcomes the ageing ... in the Proceedings of the National Academy of ... the Biotechnology and Biological Sciences Research Council (BBSRC) and ... the possibilities of alleviating ageing and age-related characteristics in ...
... A striking discovery in the study of human genetics ... on EurekAlert! in 2011. Researchers found that part of ... that they interbred with early human populations. Breakthroughs ... in zoology, psychology, and astrobiology, were also featured in ...
Cached Biology News:Leading German Researcher awarded Elsevier's 2011 Tetrahedron Prize 2Immortal worms defy aging 2Immortal worms defy aging 3Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 2Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 3Story on human genetic origins is one of EurekAlert!’s most-visited releases in 2011 4